LENZ Therapeutics (LENZ) News Today → What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (From Weiss Ratings) (Ad) Free LENZ Stock Alerts $15.29 -0.22 (-1.42%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30 at 8:00 AM | globenewswire.comLENZ Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 15, 2024 | insidertrades.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Director James W. Mccollum Purchases 31,332 SharesMay 14, 2024 | marketbeat.comInsider Buying: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Director Acquires 31,332 Shares of StockLENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) Director James W. Mccollum purchased 31,332 shares of the business's stock in a transaction on Monday, May 13th. The stock was purchased at an average cost of $15.99 per share, with a total value of $500,998.68. Following the acquisition, the director now owns 525,565 shares in the company, valued at $8,403,784.35. The purchase was disclosed in a legal filing with the SEC, which is available at this link.May 13, 2024 | seekingalpha.comLENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call TranscriptMay 12, 2024 | msn.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2024 Earnings Call TranscriptMay 10, 2024 | marketbeat.comLeerink Partnrs Weighs in on LENZ Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:LENZ)LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Stock analysts at Leerink Partnrs cut their FY2028 earnings estimates for shares of LENZ Therapeutics in a research note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post eMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for LENZ Therapeutics Amidst Strong Clinical Progress and Market PotentialMay 8, 2024 | globenewswire.comLENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 2, 2024 | marketbeat.comLENZ Therapeutics (LENZ) to Release Quarterly Earnings on WednesdayLENZ Therapeutics (NASDAQ:LENZ) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.May 1, 2024 | globenewswire.comLENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024April 18, 2024 | morningstar.comLENZ Therapeutics IncApril 17, 2024 | marketbeat.comLENZ Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.51) Per Share, Leerink Partnrs Forecasts (NASDAQ:LENZ)LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for LENZ Therapeutics in a report released on Monday, April 15th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn ($0.51)April 17, 2024 | marketbeat.comLENZ Therapeutics' (LENZ) "Outperform" Rating Reaffirmed at Leerink PartnrsLeerink Partnrs reaffirmed an "outperform" rating on shares of LENZ Therapeutics in a research note on Monday.April 15, 2024 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Receives New Coverage from Analysts at SVB LeerinkSVB Leerink initiated coverage on LENZ Therapeutics in a research report on Monday. They issued an "outperform" rating and a $32.00 price objective on the stock.April 14, 2024 | morningstar.comLENZ Therapeutics Inc LENZApril 10, 2024 | nasdaq.comLENZ Therapeutics, Inc. Common Stock (LENZ)April 10, 2024 | markets.businessinsider.comBlindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst SaysApril 10, 2024 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Now Covered by CitigroupCitigroup started coverage on LENZ Therapeutics in a research report on Wednesday. They set a "buy" rating and a $34.00 price objective for the company.April 3, 2024 | reuters.comLenz Therapeutics' eye disease drugs meet main goal of late-stage studyApril 3, 2024 | businesswire.comLENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia TrialsApril 2, 2024 | businesswire.comLENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia TrialsMarch 31, 2024 | 247wallst.comHuge Insider Buying From Buffett, an NFL Team Owner, a New CEOMarch 27, 2024 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Research Coverage Started at Piper SandlerPiper Sandler initiated coverage on shares of LENZ Therapeutics in a research note on Wednesday. They issued an "overweight" rating and a $28.00 price objective for the company.March 26, 2024 | insidertrades.comInsider Buying: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Director Acquires 998,009 Shares of StockMarch 22, 2024 | marketbeat.comTrading was temporarily halted for "LENZ" at 09:03 AM with a stated reason of "LULD pause."March 22, 2024 | marketbeat.comTrading was temporarily halted for "LENZ" at 12:03 AM with a stated reason of "News pending." Trading set to resume at 03:03 AM. March 22, 2024 | marketbeat.comTrading was temporarily halted for "LENZ" at 03:03 AM with a stated reason of "News pending." Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (Ad)A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.” Click here to find out who they are. LENZ Media Mentions By Week LENZ Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LENZ News Sentiment▼0.930.76▲Average Medical News Sentiment LENZ News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LENZ Articles This Week▼22▲LENZ Articles Average Week Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GNFT News Today CHRS News Today CGEN News Today GLUE News Today ELEV News Today SCLX News Today ABOS News Today CMPX News Today INMB News Today OPT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LENZ) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
